---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-031356"
form_type: "8-K"
ticker: "AZTR"
cik: "0001701478"
company_name: "Azitra, Inc."
filed_at: "2024-08-12T23:59:59+00:00"
generated_at: "2026-05-31T10:04:44.189755+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Azitra Q2 net loss narrows to $2.6M; completes $10M offering, pipeline milestones set

## Summary
- Net loss of $2.6M improved from $5.1M in Q2 2023; cash and equivalents $0.8M as of June 30.
- Completed $10M follow-on offering, expected to fund operations into 2025.
- R&D expenses $1.1M (up from $0.8M); G&A $1.5M (up from $0.8M); service revenue $7,500 (down from $172k).
- Expects to dose first Netherton syndrome patient with ATR-12 in Q3 2024; plans IND for ATR-04 for EGFRi rash.
- Anticipates initial safety data from ATR-12 Phase 1b by year-end 2024, topline data by mid-2025.

## SEC filing metadata
- accession: 0001493152-24-031356
- form_type: 8-K
- ticker: AZTR
- cik: 0001701478
- company_name: Azitra, Inc.
- filed_at: 2024-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701478/000149315224031356/0001493152-24-031356-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701478/000149315224031356/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-031356
- JSON: https://secwatch.observer/filing/0001493152-24-031356.json
- Plain text: https://secwatch.observer/filing/0001493152-24-031356.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.